{"id":31713,"date":"2025-07-23T17:31:11","date_gmt":"2025-07-23T17:31:11","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/31713\/"},"modified":"2025-07-23T17:31:11","modified_gmt":"2025-07-23T17:31:11","slug":"u-s-large-and-small-scale-bioprocessing-market-size-to-surpass-usd-85-31-billion-by-2034","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/31713\/","title":{"rendered":"U.S. Large and Small-scale Bioprocessing Market Size to Surpass USD 85.31 Billion by 2034"},"content":{"rendered":"

<\/p>\n

According to Nova One Advisor, the U.S.
\nlarge and small-scale bioprocessing market size<\/a> is calculated at 29.35
\nbillion in 2024 and is projected to surpass USD 85.31 billion by 2034 with a
\nremarkable CAGR of 11.26% from 2024 to 2034.<\/p>\n

<\/p>\n

The U.S. large and small-scale bioprocessing market is
\nexpanding because they are a primary source of major drugs and biologics
\nessential for medical treatments and scientific research, and development.
\nSignificant pharma product derived from living organisms such as recombinant
\nproteins, tissues, cells, genes, blood components, allergens, and vaccines. <\/p>\n

It comprises the cultivation and manipulation of
\nbioprocessing systems on a small and large scale to attain particular
\nindustrial or scientific objectives. With this bioprocessing, the biotech
\nsector can contribute to the progress in different fields, from the food
\nindustry and the production of biomass to the novel drug development sector.<\/p>\n

The Complete Study is Now Available for Immediate Access
\n| Download the Sample Pages of this Report@ https:\/\/www.novaoneadvisor.com\/report\/sample\/9182<\/a>\n<\/p>\n

U.S. Large and Small-scale Bioprocessing Market Highlights:<\/p>\n

\u2022 By scale, the industrial scale segment dominated the
\nmarket with the largest share in 2024.<\/p>\n

\u2022 By scale, the small-scale segment is expected to show the
\nfastest growth over the forecast period.<\/p>\n

\u2022 By workflow, the downstream processing segment held the
\nlargest market share in 2024.<\/p>\n

\u2022 By workflow, the fermentation segment is expected to
\nregister significant growth during the forecast period.<\/p>\n

\u2022 By product, the bioreactors\/ fermenters segment captured
\nthe largest market share in 2024.<\/p>\n

\u2022 By product, the cell culture products segment is expected
\nto show the fastest growth during the forecast period.<\/p>\n

\u2022 By application, the biopharmaceuticals segment generated
\nthe highest market revenue in 2024. <\/p>\n

\u2022 By application, the specialty industrial chemicals segment
\nis expected to grow at a significant rate over the forecast period.<\/p>\n

\u2022 By use-type, the multi-use segment accounted for the
\nhighest market share in 2024.<\/p>\n

\u2022 By use-type, the single-use segment is expected to grow
\nsignificantly during the predicted timeframe.<\/p>\n

\u2022 By mode, the in-house segment dominated the market with
\nthe biggest revenue share in 2024. <\/p>\n

\u2022 By mode, the outsourced segment is expected to grow at the
\nfastest CAGR during the forecast period.<\/p>\n

Market Size & Forecast<\/p>\n

\u2b25\ufe0e
\n2024 Market Size: USD 29.35 Billion<\/p>\n

\u2b25\ufe0e
\n2034 Projected Market Size: USD 85.31 Billion<\/p>\n

\u2b25\ufe0e
\nCAGR (2025-2034): 11.26%<\/p>\n

\u2b25\ufe0e
\nNorth America: Largest market in 2024<\/p>\n

Market Overview and Industry Potential<\/p>\n

The U.S. large and small-scale bioprocessing market is
\nexpanding rapidly due to bioprocessing<\/a>
\nis the management of naturally occurring living organisms and systems by
\nbioengineers to attain industrial and research goals. The U.S. has an
\nunparalleled ability to grow, store, harvest, and transport bioprocessing
\nproducts on a large scale. Increasing government support for small- and
\nlarge-scale bioprocessing, for instance, in 2023, the President\u2019s commitment to
\ngrow the bioeconomy spurred $46 billion in public and private sector
\nbiomanufacturing investments for projects in the country.<\/p>\n

Immediate Delivery Available | Buy This Premium Research https:\/\/www.novaoneadvisor.com\/report\/checkout\/9182<\/a>\n<\/p>\n

Top Used Bioprocesses Across the Globe:<\/p>\n

Processes<\/p>\n

Application<\/p>\n

Bioreactor
\n operation<\/p>\n

It ensures an
\n ideal environment for cell growth and the synthesis of desired bioproducts,
\n enabling the optimization of bioprocesses and reducing costs. <\/p>\n

Upstream
\n bioprocessing<\/p>\n

This process
\n helps to develop therapeutic proteins, stem cells, and viruses.<\/p>\n

Fermentation<\/p>\n

Optimization
\n of fermentation and bioprocessing is crucial to maximize production and
\n improve the efficiency of these processes.<\/p>\n

Distillation<\/p>\n

It is not
\n only used for product recovery but also for product purification.<\/p>\n

\u00a0<\/p>\n

Chromatography<\/p>\n

Chromatography
\n is a powerful technique for the separation and purification of products.<\/p>\n

\u00a0<\/p>\n

U.S. DOE about Biotech Sector:<\/p>\n

The U.S. Department of Energy (DOE) is initiating to use of biotechnology<\/a>
\nand biomanufacturing to enhance the lives of U.S. people and is taking
\nsignificant steps to advance the National Biomanufacturing and Biotechnology
\nInitiative. Increasing government funding for advanced biomanufacturing.<\/p>\n

\u2022For instance, in August 2024, the US Department of
\nAgriculture is assuring a $25 million loan for a contract fermentation facility
\nLiberation Labs is building in Indiana, which will contribute to the growth of
\nthe market.<\/p>\n

\u2022 For Instance, In April 2025, Manus, the proven
\nbioalternatives scale-up platform, and Inscripta, a leading life science
\ntechnology company helping to create the bioeconomy, announced a strategic
\nmerger to establish a unique end-to-end platform for scalable development,
\nbiomanufacturing, and commercialization of bioalternative products.<\/p>\n

Latest Trends of the Market<\/p>\n

\u2b25\ufe0e
\nIn September 2022, the US government invested over $2 billion to launch its
\nbiomanufacturing initiative, whose goal is to expand manufacturing capacity in
\nthe country and ensure pandemic preparedness.<\/p>\n

\u2b25\ufe0e
\nIn January 2025, U.S. Department of Agriculture (USDA) Secretary Tom Vilsack
\nannounced that USDA is funding 586 projects to increase access to clean energy
\nsystems and enhance the availability of domestic biofuels. Today, USDA is
\nproviding nearly $180 million through the Rural Energy for America Program
\n(REAP) and the Higher Blends Infrastructure Incentive Program (HBIIP) with
\nfunding from President Biden\u2019s Inflation Reduction Act, the nation\u2019s
\nlargest-ever investment in combatting the climate crisis. <\/p>\n

\u2b25\ufe0e
\nIn May 2025, DuPont expanded its bioprocessing portfolio with the launch of
\nDuPont AmberChrom TQ1 chromatography resin for the purification of
\noligonucleotides and peptides in support of a broad range of biopharma
\napplications.<\/p>\n

Increasing Demand for Biopharma: Market\u2019s Largest
\nPotential<\/p>\n

Growing demand for biopharma products as the U.S. is a
\nglobal leader in biopharmaceutical<\/a>
\nR&D, around half of the worldwide biopharma R&D activities are
\nhosted in the U.S. It leads because to its large domestic sector, IP
\nprotections, limits on government drug price setting, supportive science
\ninitiative, and helpful innovation clusters. The U.S. has a long history of
\noriginally leading in progressive industries, only to subsequently lose its
\ncompetitive benefits to other countries with more efficient industrial
\npolicies. The US government has recently been threatening a 25% tariff on
\npharmaceuticals imported to the US to inspire more biopharma companies to
\nonshore manufacturing. These tariffs could add up to $750 million in costs,
\nwhich contributes to the growth of U.S. large and small-scale bioprocessing.<\/p>\n

\u2b25\ufe0e
\nFor Instance, In April 2025, Asahi
\nKasei Bioprocess America, Inc<\/a>. (AKBA), a leader in advanced filtration
\nand fluid management solutions for the biopharmaceutical industry, was
\nrecognized with the Best Technologies Innovation Award at INTERPHEX 2025. This
\nrecognition was for AKBA\u2019s THESYS Cleavage & Deprotection (C&D) and
\nTangential Flow Filtration (TFF) unit, a groundbreaking system redefining
\noligonucleotide manufacturing efficiency. <\/p>\n

Report Scope of U.S. Large and
\nSmall-scale Bioprocessing Market<\/p>\n

Report Coverage<\/p>\n

Details<\/p>\n

Market Size in 2025<\/p>\n

USD 32.65 Billion<\/p>\n

Market Size by 2034<\/p>\n

USD 85.31 Billion<\/p>\n

Growth Rate From 2025
\n to 2034<\/p>\n

CAGR of 11.26%<\/p>\n

Base Year<\/p>\n

2024<\/p>\n

Forecast Period<\/p>\n

2025-2034<\/p>\n

Segments Covered<\/p>\n

Scale, Workflow,
\n Product, Application, Mode, Use-type<\/p>\n

Market Analysis
\n (Terms Used)<\/p>\n

Value (US$
\n Million\/Billion) or (Volume\/Units)<\/p>\n

Key Companies
\n Profiled<\/p>\n

Avantor, Inc.,
\n Bio-Synthesis, Inc., Corning Inc., Danaher (Cytiva), Distek, Inc., Entegris,
\n Eppendorf AG, F. Hoffmann-La Roche Ltd, Getinge AB, Lonza, Meissner
\n Filtration Products, Inc., Merck KGaA (MilliporeSigma),Thermo Fisher
\n Scientific, Inc., PBS Biotech, Inc., Repligen Corporation, Saint-Gobain,
\n Sartorius AG<\/p>\n

\u00a0<\/p>\n

U.S. Large and Small-scale Bioprocessing Market
\nSegmentation Analysis:<\/p>\n

By Scale Analysis:<\/p>\n

The industrial scale segment dominates in the U.S. large and
\nsmall-scale bioprocessing market, as this bioprocessing involves the production
\nof pharmaceuticals, flavours, foods, fuels, and chemicals with the help of a
\nbiocatalyst like an enzyme, microorganisms, plant cells, or animal cells within
\na bioreactor. They classically engage in widespread manufacturing, service
\nprovision, or processing, also influencing worldwide sectors and economies.
\nThese industries benefit from economies of scale, allowing them to produce
\nservices or goods more professionally and at minimal expenses compared to
\nsmaller businesses. <\/p>\n

On the other hand, the small-scale segment is expected to
\ngrow significantly during the forecast period as it offers increased
\nflexibility, affordability, and reduced cross-contamination challenges. This
\ntype of manufacturing often contains the application of manual labor and simple
\nmachinery or devices.<\/p>\n

By Workflow Analysis:<\/p>\n

The downstream
\nprocessing<\/a> segment dominates the U.S. large and small-scale
\nbioprocessing market, as this processing refers to the series of unit
\noperations used to separate, purify, and concentrate the product. Downstream
\nprocessing also identifies the economic feasibility of the process. The first
\noperation is cell separation, which is done by cross-flow microfiltration. This
\nprocessing generally involves numerous stages, including cell separation,
\nproduct recovery, and purification to achieve a high level of product purity.<\/p>\n

The fermentation<\/a>
\nsegment is expected to grow significantly during the forecast period, as it is
\nsuitable for entirely kinds of environments. It is the oldest metabolic process
\nthat is common to prokaryotes and eukaryotes. Fermentation is broadly used in
\ndifferent industries. Fermentation makes food nutritious, digestible, and
\nflavoured. Fermentation is an ordinary way of enhancing vitamins, essential
\namino acids, anti-nutrients, food appearance, proteins, and improved aroma.<\/p>\n

By Product Analysis:<\/p>\n

The bioreactors\/ fermenters segment captured the largest
\nmarket share in 2024, as it is the core of any biologica process in which
\nmicrobial, enzymes, plant, or mammalian cell systems are used for the
\nmanufacture of a broad range of valuable biological products. The performance
\nof any bioreactor is based on many functions, such as biomass concentration and
\nSterile conditions. Bioreactors ensure a perfect environment for cell growth
\nand the synthesis of wanted bioproducts, allowing the optimization of
\nbioprocesses and lowering costs and production time.<\/p>\n

The cell culture products segment is expected to show the
\nfastest growth during the forecast period, as cell cultures have huge control
\nof the physicochemical environment, such as pH, temperature, osmotic pressure,
\noxygen, and carbon dioxide tension, which can be controlled precisely, and the
\ncontrol of physiological conditions, which can be constantly examined. Cell
\nculture is used as an ideal system to study basic cell biology and
\nbiochemistry, to study the interaction among the cells and disease-causing
\nagents such as viruses, bacteria, and to study the effects of drugs.<\/p>\n

By Application Analysis:<\/p>\n

The biopharmaceuticals<\/a>
\nsegment generated the highest market revenue in 2024, as bioprocessing is a
\nmoderately advanced concept in the manufacturing of biopharmaceuticals.
\nEntirely of the active pharmacological ingredients must be sterile for their
\nadministration. Thus, they must be produced under sterile conditions. It
\nrevolutionizes the massive mainstream biomanufacturing process steps in
\naccommodations of biopharmaceutical industries. There is high potential in
\nmaking processes more affordable due to customization and simplification of
\nsome aspects of bioprocessing technology and reducing the cost of products.<\/p>\n

\"A<\/p>\n

The specialty industrial chemicals segment is expected to
\nregister the fastest CAGR during the predicted timeframe as bioprocesses over
\ntraditional chemical processes require mild reaction conditions, are more
\nefficient and specific, and produce renewable by-products. The expansion of recombinant
\nDNA technology<\/a> has prolonged and extended the potential of
\nbioprocesses.<\/p>\n

By Use-Type Analysis:<\/p>\n

The multi-use segment generated the highest market revenue
\nin 2024, as large-scale multi-use processes are time-saving technologies in the
\nworld. Although they have demonstrated process effectiveness, a company
\nconsiders major aspects when acquiring it. Large-scale multi-use processes
\noften evolve as customized solutions. It requires high capital investment and
\noperational costs, and the device’s footprint is large.<\/p>\n

The single-use chemicals segment is expected to register the
\nfastest CAGR during the predicted timeframe, as it is alternative solutions
\nhave become available for commercial cell-culture\u2013based manufacturing.
\nSingle-use technology is intended to be disposable, meaning it almost
\neliminates the challenges of leftover contamination between manufacturing runs.\n<\/p>\n

By Mode Analysis:<\/p>\n

The in-house segment generated the highest market revenue in
\n2024, as this manufacturing allows for product development as rapidly and as
\neconomically as possible because consumers have control over it. Therefore,
\nin-house approaches are critical for CGT entrants and drug developers that are
\ndesignated to become fully integrated companies.<\/p>\n

The outsourced segment is expected to register the fastest
\nCAGR during the predicted timeframe as outsourcing bioprocess development
\nprovides many advantages. This includes the opportunity and potential to
\naccelerate the bioprocess development timeline, allowing companies to enter
\npre-clinical studies quicker and to enroll their drug in clinical trials in a
\ntime-efficient manner.<\/p>\n

Country Level Analysis:<\/p>\n

The U.S. is dominant in the market as a presence of robust
\nproduct pipelines in gene and cell therapies, tissue engineering, and more is
\ndriving demand for large and small-scale bioprocessing. U.S. government to
\nbuild more databases, progress standards, raise R&D funding opportunities,
\nand increase consumer facilities for scale-up. Increasing government support
\nfrom NIH, BARDA, and private investors drives the infrastructure and innovation.<\/p>\n

\u2b25\ufe0e
\nFor Instance, In April 2025, Thermo Fisher Scientific<\/a>
\nannounced a $2 billion investment in US operations over the next four years to
\nbolster domestic innovation and manufacturing capabilities in the life sciences
\nsector. According to the company, the investment consists of $1.5 billion in
\ncapital expenditures to expand manufacturing and $500 million towards R&D
\naimed at supporting high-impact innovations.<\/p>\n

U.S. Large and Small-scale Bioprocessing Market
\nCompanies:<\/p>\n

\u2022 Avantor,
\nInc<\/a>.<\/p>\n

\u2022 Bio-Synthesis, Inc<\/a>.<\/p>\n

\u2022 Corning Inc.<\/p>\n

\u2022 Danaher (Cytiva)<\/p>\n

\u2022 Distek, Inc<\/a>.<\/p>\n

\u2022 Entegris<\/p>\n

\u2022 Eppendorf AG<\/a><\/p>\n

\u2022 F. Hoffmann-La Roche Ltd<\/p>\n

\u2022 Getinge AB<\/a><\/p>\n

\u2022 Lonza<\/a><\/p>\n

\u2022 Meissner Filtration Products, Inc.<\/p>\n

\u2022 Merck KGaA (MilliporeSigma)<\/p>\n

\u2022 Thermo Fisher Scientific, Inc.<\/p>\n

\u2022 PBS Biotech, Inc<\/a>.<\/p>\n

\u2022 Repligen Corporation<\/p>\n

\u2022 Saint-Gobain<\/p>\n

\u2022 Sartorius AG<\/p>\n

What is Going Around the Globe?<\/p>\n

\u2b25\ufe0e
\nIn June 2025, Ecolab Life Sciences launched its new Purolite AP+50 affinity
\nchromatography resin at the Biotechnology Innovation Organization (BIO)
\nInternational Convention, which is being held in Boston. The new resin
\noptimizes operations during the antibody manufacturing process.<\/p>\n

\u2b25\ufe0e
\nIn April 2025, Culture Biosciences, headquartered in South San Francisco,
\nCalif., announced the launch of Stratyx 250, which the company said in a press
\nrelease is the first mobile, cloud-integrated bioreactor that is designed to
\nprovide biotech companies with simultaneous flexibility, automation, and remote
\nprocess control.<\/p>\n

You can place an order or ask any questions, please feel
\nfree to contact at\u00a0sales@novaoneadvisor.com<\/a>
\n\u00a0| +1 804 441 9344<\/p>\n

Related Report \u2013<\/p>\n

\u2b25\ufe0e
\nU.S. Single-use Bioprocessing Market – https:\/\/www.novaoneadvisor.com\/report\/us-single-use-bioprocessing-market<\/a>\n<\/p>\n

\u2b25\ufe0e
\nSingle-use Bioprocessing Market – https:\/\/www.novaoneadvisor.com\/report\/single-use-bioprocessing-market<\/a>\n<\/p>\n

\u2b25\ufe0e
\nIndia Single-use Bioprocessing Probes And Sensors Market – https:\/\/www.novaoneadvisor.com\/report\/india-single-use-bioprocessing-probes-and-sensors-market<\/a>\n<\/p>\n

\u2b25\ufe0e
\nSingle-use Bioprocessing Probes & Sensors Market- https:\/\/www.novaoneadvisor.com\/report\/single-use-bioprocessing-probes-sensors-market<\/a>\n<\/p>\n

\u2b25\ufe0e
\nSingle-use Bioprocessing Probes And Sensors Market – https:\/\/www.novaoneadvisor.com\/report\/single-use-bioprocessing-probes-and-sensors-market<\/a>\n<\/p>\n

\u2b25\ufe0e
\nContinuous Bioprocessing Market – https:\/\/www.novaoneadvisor.com\/report\/continuous-bioprocessing-market<\/a>\n<\/p>\n

Segments Covered in the Report<\/p>\n

This report forecasts revenue growth at country levels and
\nprovides an analysis of the latest industry trends in each of the sub-segments
\nfrom 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the
\nU.S. large and small-scale bioprocessing market.<\/p>\n

By Scale<\/p>\n

\u2022 Industrial Scale (Over 50,000 Liter)<\/p>\n

\u2022 Small Scale (Less Than 50,000 Liter)<\/p>\n

By Workflow<\/p>\n

\u2022 Downstream Processing<\/p>\n

\u2022 Fermentation<\/p>\n

\u2022 Upstream Processing<\/p>\n

By Product<\/p>\n

\u2022 Bags & Containers<\/p>\n

\u2022 Bioreactors\/Fermenters<\/p>\n

\u2022 Bioreactors Accessories<\/p>\n

\u2022 Cell Culture Products<\/p>\n

\u2022 Filtration Assemblies<\/p>\n

\u2022 Others<\/p>\n

By Application<\/p>\n

\u2022 Biopharmaceuticals<\/p>\n

\u2022 Environmental Aids<\/p>\n

\u2022 Speciality Industrial Chemicals<\/p>\n

By Use-Type<\/p>\n

\u2022 Multi-Use<\/p>\n

\u2022 Single-Use<\/p>\n

By Mode<\/p>\n

\u2022 In-House<\/p>\n

\u2022 Outsourced<\/p>\n

Immediate Delivery Available | Buy This Premium Research https:\/\/www.novaoneadvisor.com\/report\/checkout\/9182<\/a>\n<\/p>\n

About-Us<\/p>\n

Nova One Advisor is a global leader in market
\nintelligence and strategic consulting, committed to delivering deep,
\ndata-driven insights that power innovation and transformation across
\nindustries. With a sharp focus on the evolving landscape of life sciences, we
\nspecialize in navigating the complexities of cell and gene therapy, drug
\ndevelopment, and the oncology market, enabling our clients to lead in some of
\nthe most revolutionary and high-impact areas of healthcare.<\/p>\n

Our expertise spans the entire biotech and
\npharmaceutical value chain, empowering startups, global enterprises, investors,
\nand research institutions that are pioneering the next generation of therapies
\nin regenerative medicine, oncology, and precision medicine. <\/p>\n

Web: https:\/\/www.novaoneadvisor.com\/<\/a><\/p>\n

Contact Us<\/p>\n

USA:\u00a0+1 804 420 9370<\/p>\n

Email: sales@novaoneadvisor.com<\/a><\/p>\n

For Latest Update Follow Us: LinkedIn<\/a> <\/p>\n

\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"According to Nova One Advisor, the U.S. large and small-scale bioprocessing market size is calculated at 29.35 billion…\n","protected":false},"author":2,"featured_media":31714,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[28,112],"class_list":{"0":"post-31713","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-markets"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/31713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=31713"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/31713\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/31714"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=31713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=31713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=31713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}